Huntington National Bank cut its holdings in C R Bard Inc (NYSE:BCR) by 97.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 350 shares of the medical instruments supplier’s stock after selling 12,251 shares during the quarter. Huntington National Bank’s holdings in C R Bard were worth $116,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Havens Advisors LLC lifted its stake in C R Bard by 105.3% in the third quarter. Havens Advisors LLC now owns 25,000 shares of the medical instruments supplier’s stock valued at $8,013,000 after buying an additional 12,823 shares during the period. Atlantic Trust Group LLC lifted its stake in C R Bard by 19.6% in the third quarter. Atlantic Trust Group LLC now owns 14,382 shares of the medical instruments supplier’s stock valued at $4,609,000 after buying an additional 2,359 shares during the period. JPMorgan Chase & Co. lifted its stake in C R Bard by 16.3% in the third quarter. JPMorgan Chase & Co. now owns 542,368 shares of the medical instruments supplier’s stock valued at $173,222,000 after buying an additional 76,185 shares during the period. Cubist Systematic Strategies LLC lifted its stake in C R Bard by 294.2% in the third quarter. Cubist Systematic Strategies LLC now owns 3,587 shares of the medical instruments supplier’s stock valued at $1,150,000 after buying an additional 2,677 shares during the period. Finally, Comerica Bank lifted its stake in C R Bard by 6.9% in the third quarter. Comerica Bank now owns 26,081 shares of the medical instruments supplier’s stock valued at $8,525,000 after buying an additional 1,676 shares during the period. 79.11% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Jim C. Beasley sold 15,044 shares of the company’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $332.00, for a total transaction of $4,994,608.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jim C. Beasley sold 3,395 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $332.00, for a total value of $1,127,140.00. Following the sale, the insider now owns 25,630 shares of the company’s stock, valued at approximately $8,509,160. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,546 shares of company stock valued at $10,826,150. Corporate insiders own 0.80% of the company’s stock.

Several equities analysts have issued reports on BCR shares. Needham & Company LLC reissued a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th. Cowen restated a “hold” rating and set a $317.00 price objective on shares of C R Bard in a report on Friday, November 3rd. Barclays boosted their price objective on C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a report on Monday, November 6th. ValuEngine downgraded C R Bard from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, Zacks Investment Research upgraded C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price objective for the company in a report on Tuesday, December 26th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $320.83.

The firm has a market cap of $24,140.00, a P/E ratio of 43.64, a P/E/G ratio of 2.53 and a beta of 0.52. C R Bard Inc has a fifty-two week low of $223.02 and a fifty-two week high of $337.73. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37.

ILLEGAL ACTIVITY NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2018/02/11/c-r-bard-inc-bcr-holdings-cut-by-huntington-national-bank.html.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.